Details for Patent: 9,044,402

Which drugs does patent 9,044,402 protect, and when does it expire?

Patent 9,044,402 protects ARYMO ER and is included in one NDA.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 9,044,402

Title:	Abuse-deterrent pharmaceutical compositions for controlled release
Abstract:	The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.
Inventor(s):	Tygesen; Peter Holm (Vaerlose, DK), Lindhardt; Karsten (Haslev, DK), Olsen; Martin Rex (Holbaek, DK), Fischer; Gina Engslev (Vaerlose, DK), Overgard; Jan Martin (Frederikssund, DK), Boye; Georg (Hedehusene, DK), Skak; Nikolaj (Virum, DK), Elhauge; Torben (Copenhagen K, DK)
Assignee:	EGALET LTD. (London, GB)
Application Number:	14/249,965
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,044,402
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 9,044,402

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-001	Jan 9, 2017		DISCN	Yes	No			Y			MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-002	Jan 9, 2017		DISCN	Yes	No			Y			MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-003	Jan 9, 2017		DISCN	Yes	No			Y			MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Foreign Priority and PCT Information for Patent: 9,044,402

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2012 70405	Jul 6, 2012

International Family Members for US Patent 9,044,402

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013285988
Brazil	112015000150
Canada	2877183
China	104684548